Caso Clínico 02-2022.  Mujer de 68 años con macroglosia y parestesias de miembros inferiores

Héctor Sosa; Evelyn Mejía; María Fernanda Castañeda

doi:10.20453/rmh.v33i2.4250

Héctor Sosa Servicio de Medicina Interna, Departamento de Medicina, Hospital Nacional Cayetano Heredia. Ministerio de Salud. Lima, Perú.
Evelyn Mejía Servicio de Hematología, Departamento de Medicina, Hospital Nacional Cayetano Heredia. Ministerio de Salud. Lima, Perú.
María Fernanda Castañeda Servicio de Medicina Interna, Departamento de Medicina, Hospital Nacional Cayetano Heredia. Ministerio de Salud. Lima, Perú.

DOI: https://doi.org/10.20453/rmh.v33i2.4250

Referencias

Murthy P, Laing MR. Macroglossia. BMJ. 1994 Nov 26; 309(6966):1386-7.

Topouzelis N, Iliopoulos C, Kolokitha OE. Macroglossia. Int Dent J. 2011 Apr; 61(2):63-9. doi: 10.1111/j.1875-595X.2011.00015.x.

Xavier SD, Bussoloti IF, Müller H. Macroglossia secondary to systemic amyloidosis: case report and literature review. Ear Nose Throat J. 2005; 84:358–61.

Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997; 25:898-909.

Wittmann A., Macroglossia in acromegaly and hypothyroidism, Virchows Arch A Pathol Anat Histol. 1977 Apr 29; 373(4):353-60. doi: 10.1007/BF00432533.

Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008 Mar; 37(1):101-22, viii. doi: 10.1016/j.ecl.2007.10.002.

Gutch M, Annesh B, Sukriti K, et al. Macroglossia: An Uncommon Manifestation of Primary Hypothyroidism due to Hashimoto’s Thyroiditis in a Teenage Child. J ASEAN Fed Endocr Soc. 2017; 32(1):47-49. doi: 10.15605/jafes.032.01.08.

Rizer FM, Schechter GK, Richardson MA. Macroglossia: etiologic considerations and management techniques. Int J pediatr otorhinolaryngol, 1985; 8(3):225-236.

Wechalekar A, Schonland S, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25; 121(17):3420-7. doi: 10.1182/blood-2012-12-473066.

Lilleness B, Ruberg F, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019; 133(3):215-223.

Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020 Dec 3; 136(23):2620-2627. doi: 10.1182/blood.2020006913.

Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019 Dec 19; 134(25):2271-2280. doi: 10.1182/blood.2019000834.

Angiero F, Seramondi R, Magistro S. Amyloid Deposition in the Tongue: Clinical and Histopathological Profile. Anticancer Res. 2010 Jul; 30(7):3009-14.

Kastritis E, Palladini G, Minnema M. et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021; 385:46-58. DOI: 10.1056/NEJMoa2028631.